Teva is prepared to leave no stone unturned in defending itself following the European Commission’s preliminary finding that the Israeli firm breached EU antitrust rules over Copaxone (glatiramer acetate), including by “artificially expanding” the multiple sclerosis treatment’s patent life to delay generic competition.
As part of its two-pronged preliminary finding, the Commission said that Teva had also “systematically spread misleading information about a competing
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?